Management of Acute Variceal Bleeding in Patients on Carvedilol

Rationale for Discontinuation of Beta-Blockers

The European Association for the Study of the Liver (EASL) guidelines recommend discontinuing non-selective beta-blockers (NSBBs) in patients who develop acute intercurrent conditions such as bleeding, regardless of current hemodynamic stability 1, 2
Beta-blockers can mask ongoing hemorrhage and delay recognition of hemodynamic deterioration by decreasing blood pressure and blunting the physiologic tachycardic response to bleeding 3
The acute bleeding episode itself represents a contraindication to beta-blocker therapy, independent of blood pressure readings at a single time point 4, 3

The EASL guidelines recommend discontinuing carvedilol/NSBBs immediately upon diagnosis of acute variceal bleeding 1, 2
Vasoactive drugs (somatostatin, octreotide, or terlipressin) should be initiated as soon as variceal hemorrhage is suspected, even before endoscopic confirmation 1, 5
A restrictive transfusion strategy should be implemented, transfusing at hemoglobin ≤7 g/dL with a target of 7-9 g/dL 1, 5

After recovery, the optimal regimen is combination therapy, including restarting carvedilol (or propranolol if carvedilol is not tolerated) at maximal tolerated dose, plus endoscopic band ligation every 1-4 weeks until variceal eradication 3
This combination reduces rebleeding rates to 14-23% versus 38-47% for ligation alone 3

Beta-blockers should not be continued during active bleeding based solely on "stable" vital signs at presentation—the acute bleeding episode itself mandates discontinuation 1, 2, 3
Vasoactive drug initiation should not be delayed while waiting for endoscopy—start somatostatin/octreotide immediately upon clinical suspicion 5
Over-transfusion should be avoided, as excessive blood products can paradoxically increase portal pressure and worsen bleeding 1, 5